ASCO Voice of China丨Professor Ying Fan: Breaking the mTNBC 2L+ Treatment Ceiling, China’s First TROP2 ADC, LuKangsa-Tropozumab, Leads to Longer PFS Benefits

ASCO Voice of China丨Professor Ying Fan: Breaking the mTNBC 2L+ Treatment Ceiling, China’s First TROP2 ADC, LuKangsa-Tropozumab, Leads to Longer PFS Benefits

The 60th American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 31 to June 4, 2024, in Chicago, USA. During the meeting, Professor Binghe Xu from the Chinese Academy of Medical Sciences Cancer Hospital presented groundbreaking results from the phase III OptiTROP-Breast01 study of China's first original TROP2 ADC, LuKangsa-Tropozumab (SKB264). This study, led by Professor Xu, primarily targeted advanced triple-negative breast cancer (TNBC) in China and showed that LuKangsa-Tropozumab achieved a median progression-free survival (PFS) of 6.7 months, an objective response rate (ORR) of 45.4%, and a significant improvement in overall survival (OS), making it the current TROP2 ADC with the best mPFS for TNBC. In this edition of "ASCO Voice of China," Professor Ying Fan shares insights into this pioneering achievement
EASL 2024 Hot Review | Professor Hai Li: The Role of Immunosuppression and Microbiome Variations in Liver Disease Progression

EASL 2024 Hot Review | Professor Hai Li: The Role of Immunosuppression and Microbiome Variations in Liver Disease Progression

Acute-on-chronic liver failure (ACLF) is a complex syndrome characterized by acute deterioration of liver function in patients with chronic liver disease, accompanied by high mortality rates due to liver and extrahepatic organ failure. The short-term mortality rate of medical comprehensive treatment for ACLF can reach 50% to 90%. Given the high mortality and complex pathogenesis, research and treatment strategies for ACLF are particularly important. At the 2024 European Association for the Study of the Liver (EASL) Annual Meeting, Professor Hai Li from Renji Hospital, affiliated with Shanghai Jiao Tong University, provided insightful commentary on three significant research findings in the ACLF field. These studies delve into the roles and effects of immunosuppression and microbiome variations in acute decompensation (AD) of cirrhosis and ACLF, offering new perspectives for understanding the complex mechanisms of liver disease progression and potential targets for developing new ACLF treatment strategies.
Professor Wenyan Chen: Perseverance and Commitment—10-Year Follow-Up Results of the Phase III PANTHER Trial

Professor Wenyan Chen: Perseverance and Commitment—10-Year Follow-Up Results of the Phase III PANTHER Trial

Numerous studies have confirmed the clinical value of postoperative adjuvant chemotherapy for early-stage breast cancer patients. However, the cardiotoxicity and hematologic adverse reactions associated with high-dose chemotherapy remain significant clinical challenges. Recently, the ESMO BC 2024 conference released the 10-year follow-up results of the PANTHER trial, an important study on the treatment of high-risk early breast cancer. This study revealed the efficacy differences between dose-dense tailored adjuvant chemotherapy and standard adjuvant chemotherapy, providing in-depth insights into the response of key subgroups. Oncology Frontier invited Professor Wenyan Chen from Nanchang People's Hospital to elaborate on the background, findings, clinical significance, and implications of this research.
Professor Junlong Zhuang: Interim Analysis Results of the PROact Study Further Support Combined Therapy for mHSPC Patients with HRR Gene Mutations

Professor Junlong Zhuang: Interim Analysis Results of the PROact Study Further Support Combined Therapy for mHSPC Patients with HRR Gene Mutations

Studies have found that metastatic hormone-sensitive prostate cancer (mHSPC) patients with homologous recombination repair (HRR) gene mutations progress to metastatic castration-resistant prostate cancer (mCRPC) more quickly, significantly affecting overall survival. Previous research has shown that the combination of olaparib with abiraterone and prednisone significantly improves survival in mCRPC patients. At this year's ASCO Annual Meeting, a study from Professor Hongqian Guo's team at Nanjing Drum Tower Hospital analyzed this combined treatment strategy for mHSPC patients with HRR mutations for the first time. "Oncology Frontier" invited Professor Junlong Zhuang from Nanjing Drum Tower Hospital to share the findings on-site.
Professor Lei Fan: Prospects for Treatment Strategies in Richter’s Transformation丨2024 Nanjing Lymphoma Forum

Professor Lei Fan: Prospects for Treatment Strategies in Richter’s Transformation丨2024 Nanjing Lymphoma Forum

Richter's transformation (RT), a complication of chronic lymphocytic leukemia (CLL), poses significant diagnostic and therapeutic challenges. At the "2024 Nanjing Lymphoma Forum," Professor Lei Fan from Jiangsu Provincial People's Hospital delivered an academic report titled "Research Progress in Richter's Transformation," covering the latest advancements in its definition, characteristics, molecular mechanisms, and treatment progress. Hematology Frontier had the privilege of interviewing Professor Fan, discussing the significance of the Nanjing Lymphoma Forum and his outlook on the diagnosis and treatment of Richter's transformation.
ASCO China Voice | Professor Pei Dong Leads Multiple Breakthrough Studies at the ASCO Conference

ASCO China Voice | Professor Pei Dong Leads Multiple Breakthrough Studies at the ASCO Conference

The 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) was grandly held in Chicago, USA, from May 31 to June 4, 2024. As a premier global event, ASCO gathers oncology experts from around the world to discuss the latest advancements and future trends in the field. At this year's ASCO conference, several studies led by Professor Pei Dong from the Sun Yat-sen University Cancer Prevention and Treatment Center were selected, making a significant impact on the international stage. These studies not only represent new progress in the field of urologic oncology in China but also contribute to the global development of urologic oncology. "Oncology Frontier" has summarized these studies for our readers.
Expert Commentary | Professor Lin Zhang: Efficacy and Safety of 90Y Resin Microsphere Radiation Segmentectomy for Hepatocellular Carcinoma

Expert Commentary | Professor Lin Zhang: Efficacy and Safety of 90Y Resin Microsphere Radiation Segmentectomy for Hepatocellular Carcinoma

Traditionally, radiation dosage for yttrium-90 (90Y) resin microsphere radiation segmentectomy (RS) was determined using body surface area or partition models, which often resulted in lower prescription activities. Recent studies have used the Medical Internal Radiation Dosimetry (MIRD) formula to determine radiation doses, providing higher tumor absorption doses. A recent retrospective study published in Radiology by Beth Israel Deaconess Medical Center, Harvard Medical School, demonstrated that hepatocellular carcinoma (HCC) patients receiving 90Y resin microsphere RS achieved high tumor absorption doses and sustained tumor remission with good safety profiles. International Hepatology invited Professor Lin Zhang from the Tsinghua University Affiliated Beijing Tsinghua Chang Gung Hospital Hepato-Pancreato-Biliary Interventional Center to introduce and comment on this study.
ASCO 2024 | Innovative TIL Therapy OBX-115 Offers New Hope for ICI-Resistant Melanoma Patients

ASCO 2024 | Innovative TIL Therapy OBX-115 Offers New Hope for ICI-Resistant Melanoma Patients

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 31 to June 4, Eastern Time. One study on OBX-115, an engineered tumor-infiltrating lymphocyte (TIL) therapy, garnered widespread attention. This research focuses on patients with immune checkpoint inhibitor (ICI)-resistant metastatic melanoma. Unlike traditional TIL therapy, OBX-115 has a key advantage: it does not require high-dose interleukin-2 (IL-2) systemic treatment, reducing the toxicity risk for patients. Initial results indicate that OBX-115 performs well in both safety and efficacy, providing new hope for ICI-resistant melanoma patients.
ASCO 2024 | Advances in Uveal Melanoma Treatment

ASCO 2024 | Advances in Uveal Melanoma Treatment

Uveal melanoma (UM) is a severe ocular malignant tumor that threatens patients' vision and survival. Despite some progress in treatment methods in recent years, the survival rate of patients has not significantly improved due to the lack of effective drugs, especially those that inhibit metastasis. At the ongoing 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, several rapid oral reports focused on the challenges of UM treatment and presented the latest research findings. Oncology Frontier has compiled relevant studies for readers.
Safety, Efficacy, and Biomarker Results from an Open-Label, Multicenter, Phase I Study of RP2 Alone or Combined with Nivolumab in a Cohort of Patients

Safety, Efficacy, and Biomarker Results from an Open-Label, Multicenter, Phase I Study of RP2 Alone or Combined with Nivolumab in a Cohort of Patients

Uveal melanoma (UM) is a severe ocular malignant tumor that threatens patients' vision and survival. Despite some progress in treatment methods in recent years, the survival rate of patients has not significantly improved due to the lack of effective drugs, especially those that inhibit metastasis. At the ongoing 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, several rapid oral reports focused on the challenges of UM treatment and presented the latest research findings. Oncology Frontier has compiled relevant studies for readers.